Healthcare Business

Millennium Pharmaceuticals, Becoming Part of Takeda in Japan (MLNM)

Millennium Pharmaceuticals Inc. (NASDAQ: MLNM) is being acquired.  Takeda Pharmaceuticals in Japan is paying some $8.8 Billion to acquire the biotech, which had a market cap of $5.3 Billion as of yesterday.

The cash buyout will come at $25.00 per share, roughly a 50% premium to Wednesday’s $16.35 close.  Its 52-week trading range was $9.49 to $17.19.  This is also more than a 25% premium to any prices this one has seen over the last 5-years.

This acquisition will help Takeda go from heart and diabetes into more of a cancer treatment, which will further diversify its operations.  Analysts expect Millennium to post $almost $570 million in revenues this year and $673 million in revenues next year.

You can join our open email distribution list to hear about special financings, secondary offerings, IPO’s, M&A, and more previews for other special situations in various stages.

Jon C. Ogg
April 10, 2008

Jon Ogg produces the Special Situation Investing Newsletter.  He can be reached at and he does not own securities in the companies he covers.